by Jordana Choucair | Sep 23, 2021 | Life Sciences
The FDA authorized Pfizer booster shots for people over 65 and those who are in high-risk jobs or medically vulnerable at least six months after receiving their second shot. The boosters are expected to be available within days, but who exactly will be considered...
by Jordana Choucair | Sep 22, 2021 | Life Sciences
The Biden administration is buying 187 million rapid COVID-19 tests from Abbott Laboratories and Celltrion Inc. for $1.2 billion. According to an HHS official, the deals also include options for the federal government to buy more tests. Demand for rapid tests has...
by Jordana Choucair | Sep 21, 2021 | Life Sciences
Johnson & Johnson said a second dose of its COVID-19 vaccine was 94 percent effective at preventing symptomatic disease when given two months after the first shot in a late-stage trial in the U.S. A second study found the extra dose prompted a 12-fold uptick in...
by Jordana Choucair | Sep 20, 2021 | Life Sciences
Pfizer Inc. and BioNTech SE said a late-stage clinical trial showed that their COVID-19 vaccine was safe and generated strong antibody responses in children 5 to 11 years old. However, the companies don’t yet know how well the shot protects against COVID-19 for...
by Jordana Choucair | Sep 16, 2021 | Life Sciences
Ahead of an advisory meeting tomorrow, FDA scientists released documents expressing doubt about whether COVID-19 booster shots are necessary right now. In their review, agency staff said if Pfizer’s vaccine is “still effective at preventing important...
by Jordana Choucair | Sep 15, 2021 | Life Sciences
The U.S. government plans to more directly control where COVID-19 antibody treatments are sent amid a surge in infections and hospitalizations in states with large pockets of unvaccinated people. The Biden administration bought 1.4 million additional doses of...
Recent Comments